https://pharminent.com/strategic-news-watch/strategic-news-watch-may-14-2026/ 2026-05-14T18:15:29Z Pharminent en Strategic News Watch • May 14, 2026 2026-05-14T18:15:20Z Blog https://pharminent.com/biogen-takes-tau-alzheimers-therapy-to-phase-3-despite-mid-stage-fail-prompting-cautious-optimism/ 2026-05-14T20:04:50Z Pharminent en Biogen takes tau Alzheimer's therapy to Phase 3 despite mid-stage fail, prompting cautious optimism 2026-05-14T13:26:57Z Blog https://pharminent.com/with-new-data-regenxbio-to-seek-fda-approval-of-duchenne-gene-therapy/ 2026-05-14T20:04:59Z Pharminent en With new data, Regenxbio to seek FDA approval of Duchenne gene therapy 2026-05-14T13:10:00Z Blog https://pharminent.com/biotech-leaders-pitch-pazdur-as-next-fda-chief/ 2026-05-14T20:05:01Z Pharminent en Biotech leaders pitch Pazdur as next FDA chief 2026-05-14T12:42:41Z Blog https://pharminent.com/degron-adds-40m-to-series-a-supporting-immunology-plans-for-molecular-glue-platform/ 2026-05-14T20:05:02Z Pharminent en Degron adds $40M to series A, supporting immunology plans for molecular glue platform 2026-05-14T12:22:23Z Blog https://pharminent.com/regenxbios-duchenne-gene-therapy-clears-phase-3-hurdle/ 2026-05-14T20:05:09Z Pharminent en Regenxbio's Duchenne gene therapy clears phase 3 hurdle 2026-05-14T12:19:00Z Blog https://pharminent.com/regulatory-round-up-a-month-of-key-fda-approvals-for-cancer-drugs/ 2026-05-14T20:10:53Z Pharminent en Regulatory round-up: A month of key FDA approvals for cancer drugs 2026-05-14T11:05:11Z Blog https://pharminent.com/zydus-to-acquire-assertio-in-166m-deal-2/ 2026-05-14T20:05:11Z Pharminent en Zydus to acquire Assertio in $166m deal 2026-05-14T10:35:10Z Blog https://pharminent.com/pfizer-receives-ec-approval-for-hympavzi-to-treat-haemophilia/ 2026-05-14T20:05:12Z Pharminent en Pfizer receives EC approval for Hympavzi to treat haemophilia 2026-05-14T09:37:24Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-may-13-2026/ 2026-05-14T01:36:25Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • May 13, 2026 2026-05-14T01:36:21Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-may-13-2026/ 2026-05-13T20:01:08Z Pharminent en Manufacturing Intelligence • Weekly Digest • May 13, 2026 2026-05-13T20:01:04Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-13-2026/ 2026-05-13T18:19:27Z Pharminent en Strategic News Watch • May 13, 2026 2026-05-13T18:19:23Z Blog https://pharminent.com/uniqure-replimune-shares-rise-as-fdas-makary-exits-but-path-forward-unchanged/ 2026-05-13T18:28:09Z Pharminent en UniQure, Replimune shares rise as FDA's Makary exits, but path forward unchanged 2026-05-13T15:08:13Z Blog https://pharminent.com/assertio-accepts-new-buyout-bid-ai-biotech-isomorphic-banks-2b/ 2026-05-13T18:28:12Z Pharminent en Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B 2026-05-13T14:27:40Z Blog https://pharminent.com/80624-2/ 2026-05-14T01:15:32Z Pharminent en 2026-05-13T01:14:45Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-may-12-2026/ 2026-05-12T23:29:24Z Pharminent en Oncology Intelligence Digest • May 12 2026 2026-05-12T23:29:20Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-12-2026/ 2026-05-12T23:03:30Z Pharminent en Strategic News Watch • May 12, 2026 2026-05-12T23:03:27Z Blog https://pharminent.com/80501-2/ 2026-05-12T13:06:45Z Pharminent en 2026-05-12T13:06:40Z Blog https://pharminent.com/bms-hengrui-build-13-asset-pipeline-in-15b-onco-immune-deal/ 2026-05-12T16:29:30Z Pharminent en BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal 2026-05-12T12:19:31Z Blog https://pharminent.com/eu-agrees-plan-to-tackle-essential-medicine-shortages/ 2026-05-12T16:29:34Z Pharminent en EU agrees plan to tackle essential medicine shortages 2026-05-12T12:09:07Z Blog https://pharminent.com/bridgebio-stands-up-to-pfizer-in-attr-cm-as-late-stage-data-hint-at-better-survival/ 2026-05-12T16:29:35Z Pharminent en BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival 2026-05-12T11:34:15Z Blog https://pharminent.com/novo-says-high-dose-wegovy-can-cause-28-weight-loss/ 2026-05-12T16:29:37Z Pharminent en Novo says high-dose Wegovy can cause 28% weight loss 2026-05-12T11:01:53Z Blog https://pharminent.com/340b-in-2026-market-shifts-policy-battles-and-what-they-mean-for-stakeholders-new-live-video-webinar/ 2026-05-12T16:29:39Z Pharminent en 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) 2026-05-12T10:30:00Z Blog https://pharminent.com/cellular-intelligence-scoops-up-novos-parkinsons-therapy/ 2026-05-12T16:21:17Z Pharminent en Cellular Intelligence scoops up Novo's Parkinson's therapy 2026-05-12T08:37:02Z Blog